Award

MSI Detection in Circulating Tumor DNA of Lynch Syndrome Patients

Description: Lynch syndrome is a cancer predisposition syndrome associated with up to an 80% lifetime risk of cancer development. It is one of the most common cancer syndromes. For these patients, lifelong cancer screening and risk-reducing surgeries are necessary, and many of these cancers do not have proven effective screening. Because Lynch patients have mutations in DNA mismatch repair genes (the body’s “spellchecker”) tumors characteristically show the microsatellite instability (MSI) signature. This is defined as differences in length of short DNA sequence repeats in tumor compared to normal tissue. Simply stated, the “spellchecker” cannot accurately repair these defects, they accumulate/slip, and this leads to a mismatch in the letter sequences in the now cancerous tissue. We have previously shown that this is the case in ALL Lynch-associated cancers, making this a very predictable marker for Lynch patients. Historically, MSI was assessed by testing only 5-7 known MSI slippage sites. However, our FDA-authorized bioinformatics algorithm (MSIsensor) accurately classifies tumor MSI status by using genetic tumor data that looks at over 1,000 known MSI sites, making the test highly sensitive and specific for MSI detection. Cell-free DNA (cfDNA) are nucleic acid fragments found in circulating blood, and some of that is specific to tumors found in cancer patients (ctDNA). Analyzing genetic mutations (rather than MSI) in ctDNA is currently being used as a potential non-invasive method to monitor treatment response and assess for disease recurrence. Our ctDNA test, MSK-ACCESS, is approved for clinical use by the New York State Department of Health. As part of the overall MSK-ACCESS test, over 1,000 microsatellite sites are captured. We developed a novel machine learning algorithm to leverage these sites to determine MSI status more efficiently. We have successfully detected MSI in ctDNA (MSI-ctDNA) of advanced colon cancer patients. Now, we will detect MSI-ctDNA using our platform across a larger group of Lynch-associated advanced cancers. We will also determine whether our ability to detect MSI-ctDNA varies by tumor type and tumor burden, and will compare samples collected in patients over time to assess for disease recurrence and treatment response. We will then explore the feasibility of MSI-ctDNA detection in early-stage Lynch-associated cancers before and after patients’ surgical removal of their cancers. This proposal may aid in developing a novel screening test for multiple cancers, many of which do not have current effective surveillance methods, thus speaking to the clinical utility of this project. Lynch syndrome is unique in that patients: 1) are at very high-risk of cancer, 2) develop cancers with an extremely predictable genetic profile, as MSI is a nearly universal tumor signature. This makes Lynch Syndrome patients an ideal study population for the proposed project.
Amount: $437,400
Funding type: award
Start date: 2022-01-01
End date: 2024-12-31
Investigators: Alicia Latham (lead), Philip Kantoff, Zsofia Stadler, Michael Berger, Annmarie Pacchia, Gregory Raskin, Joselin Galvez
Institutions: Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, Memorial Sloan Kettering Cancer Center (MSK)
Field: Medicine
Funded outputs count: 0
Funder award ID: CSDG-21-148-01-CDP
OpenAlex ID: G5378579755